Skip to main content
Signal8

Protalix BioTherapeutics, Inc. (PLX)

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc.

NYSE:PLXHealthcare
+0.50%$3.04
Mkt Cap$255.91M
EV-
Float81.19M
O/S84.32M
VOL1.15M sh
$ Vol$3.51M
RVOL1.17×
Inst Own19.1%
Net Cash/Sh-
Dilution
Protalix BioTherapeutics, Inc. logoNYSE:PLX$3.04+0.50%
Historical Data
DateOpenHighLowCloseVolume
Nov 19, 20262.973.142.923.041,148,588
Nov 18, 20262.893.022.883.02962,924
Nov 17, 20263.013.082.862.88896,040
Nov 16, 20263.003.072.953.031,290,382
Nov 13, 20262.943.052.853.051,588,436
Nov 12, 20263.123.132.922.962,436,756
Nov 11, 20262.863.142.783.133,092,811
Nov 10, 20262.452.962.452.863,039,600
Nov 9, 20262.532.572.502.57792,061
Nov 6, 20262.512.592.482.54364,044
Nov 5, 20262.672.682.482.51916,909
Nov 4, 20262.612.732.582.69870,832
Nov 3, 20262.572.612.522.61289,039
Nov 2, 20262.602.622.542.56726,274
Oct 30, 20262.602.632.562.59249,288
Oct 29, 20262.592.682.592.61274,762
Oct 28, 20262.512.622.472.59596,661
Oct 27, 20262.482.542.462.53448,304
Oct 26, 20262.552.552.462.48416,271
Oct 23, 20262.542.562.502.55383,908
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
5
HOLD
2
SELL
0
TOTAL7
Insider Trades
InsiderTypeShares
Ben Zvi Shmuel profile photoBen Zvi ShmuelGrant/Award17.0K
Forster Eliot profile photoForster EliotGrant/Award17.0K
Ben Zvi Shmuel profile photoBen Zvi ShmuelGrant/Award8.5K
Forster Eliot profile photoForster EliotGrant/Award8.5K
Schwartz Aharon profile photoSchwartz AharonGrant/Award17.0K
Schwartz Aharon profile photoSchwartz AharonGrant/Award8.5K
Shareholders
19.1%
Institutional
(108)
0.6%
Insiderⓘ
(6)
4.9%
5%+ Owners
(1)
75.4%
Unattributed (incl. retail)ⓘ
Institutional19.1%
Insider0.6%
5%+ Beneficial4.9%
Unattributed (incl. retail)75.4%
Top Shareholders
NameShares%
BlackRock, Inc. logo
BlackRock, Inc.
4.2M5.0%
HOLD Alapkezelo Zrt. logo
HOLD Alapkezelo Zrt.
· may incl. warrants· filed Oct 2026
4.2M4.9%
STATE STREET CORP logo
STATE STREET CORP
1.2M1.4%
GEODE CAPITAL MANAGEMENT, LLC logo
GEODE CAPITAL MANAGEMENT, LLC
997.1K1.2%
RENAISSANCE TECHNOLOGIES LLC logo
RENAISSANCE TECHNOLOGIES LLC
988.1K1.2%
GOLDMAN SACHS GROUP INC logo
GOLDMAN SACHS GROUP INC
889.4K1.1%
NORTHERN TRUST CORP logo
NORTHERN TRUST CORP
831.7K1.0%
DIMENSIONAL FUND ADVISORS LP logo
DIMENSIONAL FUND ADVISORS LP
717.0K0.9%
VANGUARD PORTFOLIO MANAGEMENT LLC logo
VANGUARD PORTFOLIO MANAGEMENT LLC
557.2K0.7%
Stratos Wealth Partners, LTD. logo
Stratos Wealth Partners, LTD.
400.0K0.5%
Sources: 13F, Form 4, 13D/13GO/S: 84.3M · as of 1 Nov 2026 · SEC filings
Insiders & Institutional Holders
About

Established in 1993 and based in Hackensack, New Jersey, Protalix BioTherapeutics, Inc. is a biopharmaceutical company primarily focused on advancing and globally commercializing recombinant therapeutic proteins.

The firm utilizes its proprietary ProCellEx plant cell-based protein expression system to develop these treatments, reaching patients in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and other international regions. Protalix currently offers Elelyso, a treatment for Gaucher disease.

Its robust product pipeline includes PRX-102, a therapeutic protein candidate now in late-stage clinical trials for Fabry disease. Also in development are PRX-110, a plant cell-derived recombinant human deoxyribonuclease I, which has successfully completed Phase IIa clinical trials for cystic fibrosis; PRX-115, a recombinant PEGylated Uricase expressed in plant cells for addressing gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate targeting NETs-related diseases.

The company maintains strategic alliances and collaborations with key partners such as Pfizer, Fundação Oswaldo Cruz (Fiocruz), and Chiesi Farmaceutici S.p.A.

Key Metrics
Market Cap$255.91M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership19.07%

based on 84.32M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNYSE American
CountryUSUS
IPO DateMay 15, 1998
Shares Outstanding84.32M
Authorized Shares
Float81.19M
52-Week Range
$1.65$3.19
$3.04(90th percentile)
Volume
Average Daily Volume984.36K
1.15M today vs 984.36K avg(+17%)

30d Avg

984.36K

60d Avg

941.12K

90d Avg

889.61K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Signal8's dilution snapshot of PLX as of Sep 30, 2026 records an effective S-3 shelf registration (effective Aug 22, 2025) and an at-the-market sales agreement dated Feb 27, 2023, from SEC filings. Protalix BioTherapeutics, Inc. (NYSE: PLX) traded at $3.04 on Nov 19, 2026, up 0.50% from the previous close of $3.02. 52-week range: $1.65 to $3.19. The company is in the Healthcare sector (Biotechnology).